Story

AMC Stock Climbs on Analyst Upgrade, Improved Box Office Outlook

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
AMC Stock Climbs on Analyst Upgrade, Improved Box Office Outlook

Summary

AMC Entertainment shares rose in pre-market trading after Texas Capital Securities upgraded the stock to Buy, citing the resolution of near-term debt and a stronger industry-wide box office forecast.

Text size
Background

Shares of AMC Entertainment (NYSE: AMC) climbed more than 5% in pre-open trading after an analyst upgrade and positive industry data bolstered investor sentiment. The move comes amid a broader risk-on tone in U.S. equity markets.

Analyst Upgrade Cites Debt Resolution

The primary catalyst for the stock's advance was an upgrade from Texas Capital Securities, which raised its rating on AMC shares to Buy from Hold. The firm also increased its price target on the stock to $3.00 from $2.00.

In a note, the analysts cited the resolution of near-term debt maturities as a key factor in their renewed optimism. They also highlighted that AMC's stock had declined significantly since their coverage began in May 2025, even as broader small-cap indices posted gains, making the current valuation more compelling.

Sample IUX Markets – In-articleAd

Broader Tailwinds Support Shares

Beyond the upgrade, several other factors are contributing to the positive momentum. Earlier this week, the stock saw a surge in interest from retail investors after critical comments from CNBC's Jim Cramer, a phenomenon traders refer to as an "Inverse Cramer" rally.

Adding to the positive sector outlook, Macquarie recently raised its full-year 2026 industry box office forecast. The firm pointed to stronger-than-expected U.S. admissions revenue in the second quarter, which marked the best Q2 performance for the domestic box office in six years. This improved environment benefits the entire theater exhibition industry, providing more confidence in the sector's recovery.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST